Filter your results
- 2
- 1
- 3
- 3
- 2
- 1
- 3
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Blood Advances, 2019, 3 (24), pp.4238-4251. ⟨10.1182/bloodadvances.2019000647⟩
Journal articles
hal-02442440v1
|
||
|
Reference Values for WBC Differential by Hematoflow AnalysisAmerican journal of clinical pathology, 2019, 151 (3), pp.324-327. ⟨10.1093/ajcp/aqy147⟩
Journal articles
hal-01976722v1
|
||
|
High sensitivity of the Hematoflow™ solution for chronic myelomonocytic leukemia screeningCytometry Part B: Clinical Cytometry, 2018, 94 (5), pp.658-661. ⟨10.1002/cyto.b.21600⟩
Journal articles
hal-01812481v1
|